Crosstalk between long non-coding RNAs and p53 signaling pathway in colorectal cancer: A review study
Mohammad Mahdi Khanifar,
No information about this author
Zahra Zafari,
No information about this author
Mohsen Sheykhhasan
No information about this author
et al.
Pathology - Research and Practice,
Journal Year:
2023,
Volume and Issue:
249, P. 154756 - 154756
Published: Aug. 10, 2023
Language: Английский
Long non‑coding RNAs as diagnostic and prognostic biomarkers for colorectal cancer (Review)
Yuning Lin,
No information about this author
Wenzhen Zhao,
No information about this author
Ruonan Pu
No information about this author
et al.
Oncology Letters,
Journal Year:
2024,
Volume and Issue:
28(4)
Published: Aug. 8, 2024
Colorectal
cancer
(CRC)
ranks
as
the
3rd
most
common
globally
and
is
2nd
leading
cause
of
cancer‑related
death.
Owing
to
lack
specific
early
symptoms
limitations
existing
diagnostic
methods,
patients
with
CRC
are
diagnosed
at
advanced
stages.
To
overcome
these
challenges,
researchers
have
increasingly
focused
on
molecular
biomarkers,
particular
interest
in
long
non‑coding
RNAs
(lncRNAs).
These
non‑protein‑coding
RNAs,
which
exceed
200
nucleotides
length,
play
critical
roles
development
progression
CRC.
The
stability
detectability
lncRNAs
circulatory
system
make
them
promising
candidate
biomarkers.
analysis
circulating
peripheral
blood
represents
a
potential
option
for
minimally
invasive
tests
based
liquid
biopsy
samples.
present
review
aimed
evaluate
efficacy
altered
expression
levels
markers
Additionally,
clinical
significance
prognostic
this
disease
were
summarized.
Language: Английский
Second generation androgen receptor antagonist, TQB3720 abrogates prostate cancer growth via AR/GPX4 axis activated ferroptosis
Zhongqing Zhang,
No information about this author
Tianlei Xie,
No information about this author
Shun Zhang
No information about this author
et al.
Frontiers in Pharmacology,
Journal Year:
2023,
Volume and Issue:
14
Published: Jan. 20, 2023
Purpose:
Prostate
cancer
(PCa)
poses
a
great
threat
to
humans.
The
study
aimed
evaluate
the
potential
of
TQB3720
in
promoting
ferroptosis
suppress
prostate
cancer,
providing
theoretical
basis
for
PCa
therapy.
Methods:
cells
and
nude
mice
models
were
divided
into
TQB3720,
enzalutamide
(ENZ),
control
groups.
Sulforhodamine
B
assay,
colony
formation
assessment,
organoids
culture
system,
CCK8
assay
used
detecting
proliferation.
Western
blot
was
processed
detect
expression
androgen
receptor
(AR),
ferroptosis,
apoptosis-related
genes.
Flow
cytometry
applied
measure
intracellular
ROS
levels.
ELISA
performed
determine
cellular
oxidized
glutathione
(GSSG)
malondialdehyde
(MDA)
RT-qPCR
conducted
mRNA
genes
AR
signaling.
BODIPYTM™
581/591
detection
lipid
peroxidation
interaction
with
other
translational
factor
complex
proteins
explored
using
Co-immunoprecipitation
(Co-IP),
chromatin
immunoprecipitation
(ChIP)
binding
AR-involved
downstream
promoter.
Luciferase
reporter
examine
translation
activity
GPX4
promoter,
immunohistochemistry
(IHC)
analyze
levels
c-MYC,
Ki-67
TQB3720-treated
tissues.
Results:
Here,
we
found
inhibits
growth
vitro
vivo.
treatment
induced
GSSG
MDA
significantly,
by
which
hints
antagonist
caused
ferroptosis-related
cell
death.
Moreover,
molecular
evidence
shown
regulates
signaling
resulting
inhibition
entry
nucleus.
Additional,
also
proved
that
abrogates
between
SP1
leads
decrease
transcription.
Conclusion:
promotes
reducing
AR/SP1
transcriptional
As
result,
it
is
suggested
be
drug
clinic
treatment.
Language: Английский
The functions and mechanisms of long non-coding RNA in colorectal cancer
Yuning Lin,
No information about this author
Wenzhen Zhao,
No information about this author
Zhenyi Lv
No information about this author
et al.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: July 4, 2024
CRC
poses
a
significant
challenge
in
the
global
health
domain,
with
high
number
of
deaths
attributed
to
this
disease
annually.
If
is
detected
only
its
advanced
stages,
difficulty
treatment
increases
significantly.
Therefore,
biomarkers
for
early
detection
play
crucial
role
improving
patient
outcomes
and
increasing
survival
rates.
The
development
reliable
biomarker
particularly
important
timely
diagnosis
treatment.
However,
current
methods
detection,
such
as
endoscopic
examination,
blood,
stool
tests,
have
certain
limitations
often
detect
cases
late
stages.
To
overcome
these
constraints,
researchers
turned
their
attention
molecular
biomarkers,
which
are
considered
promising
approach
detection.
Non-invasive
using
mRNA,
circulating
cell-free
DNA,
microRNA,
LncRNA,
proteins
can
provide
more
diagnostic
information.
These
be
found
tissue,
stool,
volatile
organic
compounds.
Identifying
sensitivity
specificity
safe,
economic,
easily
measurable
remains
researchers.
Language: Английский